The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study

被引：21

作者：

Drabbe, C. ^{[1
]}

Van der Graaf, W. T. A. ^{[1
,2
]}

De Rooij, B. H. ^{[3
,4
]}

Grunhagen, D. J. ^{[5
]}

Soomers, V. L. M. N. ^{[6
]}

Van de Sande, M. A. J. ^{[7
]}

Been, L. B. ^{[8
]}

Keymeulen, K. B. M., I ^{[9
]}

van der Geest, I. C. M. ^{[10
]}

Van Houdt, W. J. ^{[11
]}

Husson, O. ^{[1
,12
]}

机构：

[1] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[2] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands

[3] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[4] Tilburg Univ, Dept Med & Clin Psychol, Tilburg, Netherlands

[5] Erasmus MC Canc Inst, Dept Surg Oncol, Rotterdam, Netherlands

[6] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[7] Leiden Univ, Dept Orthopaed Surg, Med Ctr, Leiden, Netherlands

[8] Univ Med Ctr Groningen, Dept Surg Oncol, Groningen, Netherlands

[9] Maastricht Univ, Dept Surg Oncol, Med Ctr, Maastricht, Netherlands

[10] Radboud Univ Nijmegen, Dept Orthopaed, Med Ctr, Nijmegen, Netherlands

[11] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands

[12] Inst Canc Res, 15 Cotswold Rd, London SM2 5NG, England

来源：

ESMO OPEN | 2021年 / 6卷 / 01期

关键词：

sarcoma; health-related quality of life; survivorship; age-related; adolescents and young adults; PATIENT-REPORTED OUTCOMES; SOFT-TISSUE; CANCER SURVIVORSHIP; YOUNG-ADULTS; EUROPEAN-ORGANIZATION; CLINICAL-TRIALS; UK GUIDELINES; EXPERIENCE; MANAGEMENT; ADOLESCENTS;

D O I：

10.1016/j.esmoop.2021.100047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Health-related quality of life (HRQoL) data of sarcoma survivors are scarce and the impact of age remains unclear. The aims of this population-based study were to (i) compare HRQoL scores amongst three age-groups [adolescents and young adults (AYA, aged 18-39 years), older adults (OA, aged 40-69 years) and elderly (aged >= 70 years)]; (ii) compare HRQoL of each sarcoma survivor age group with an age- and sex-matched normative population sample; (iii) determine factors associated with low HRQoL per age group. Methods: Dutch sarcoma survivors, who were 2-10 years after diagnosis, were invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-questions questionnaire on HRQoL. Results: In total, 1099 survivors (58% response rate) completed the questionnaire: 186 AYAs, 748 OAs and 165 elderly. The median time since diagnosis for all patients was 5.2 years. Bone sarcomas were seen in 41% of AYAs, 22% of OAs and in 16% of elderly survivors (P < 0.01). AYA and OA survivors reported statistically significant and clinically meaningful worse physical, role, cognitive, emotional and social functioning compared with a matched norm population, which was not the case for elderly survivors. AYAs reported significantly worse scores on emotional and cognitive functioning compared with OA and elderly survivors. Malignant peripheral nerve sheath tumour, osteosarcoma and chordoma were the subtypes of which survivors reported the lowest HRQoL scores in comparison with the norm. For all age groups, chemotherapy, having a bone sarcoma and having comorbidities were most frequently associated with low scores on HRQoL subscales, whereas a shorter time since diagnosis was not. Conclusion: In this nationwide sarcoma survivorship study, the disease and its treatment had relatively more impact on the HRQoL. of AYA and OA survivors than on elderly survivors. These results emphasise the need for personalised followup care that not only includes risk-adjusted care related to disease relapse, but also age-adjusted care.

引用

页数：9